Cargando…

Impact of Covid-19 on the management of patients with metastatic melanoma

The Covid-19 pandemic created new uncertainties in the management of metastatic melanoma patients. In particular, the impact of immunotherapy, targeted therapy, or chemotherapy on the risk of Sars-CoV-2 infection and severity was debated. In this study, we analyzed all patients with metastatic melan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Welti, Michèle, Cheng, Phil F., Mangana, Joanna, Levesque, Mitchell P., Dummer, Reinhard, Imhof, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799324/ https://www.ncbi.nlm.nih.gov/pubmed/36580495 http://dx.doi.org/10.18632/oncotarget.28333

Ejemplares similares

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023)

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis
por: Ziegler, Johanna S., et al.
Publicado: (2020)

How I treat metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2019)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
por: Kaufmann, Corina, et al.
Publicado: (2020)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2021)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

A new B-Raf inhibitor combo for advanced melanoma
por: Barysch, Marjam-Jeanette, et al.
Publicado: (2018)

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
por: Dummer, Reinhard, et al.
Publicado: (2023)

The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma
por: Boerlin, Aurelio, et al.
Publicado: (2022)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
por: Kraehenbuehl, Lukas, et al.
Publicado: (2023)

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
por: Guendisch, Ulf, et al.
Publicado: (2022)

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
por: Mangana, Joanna, et al.
Publicado: (2017)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

The A to I editing landscape in melanoma and its relation to clinical outcome
por: Amweg, Austeja, et al.
Publicado: (2022)

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Correction: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
por: Czyż, Małgorzata, et al.
Publicado: (2016)

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
por: Raaijmakers, Marieke I. G., et al.
Publicado: (2016)

The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2017)

Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma
por: Tusup, Marina, et al.
Publicado: (2021)

Evolving impact of long-term survival results on metastatic melanoma treatment
por: Michielin, Olivier, et al.
Publicado: (2020)

Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2018)

Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread
por: Ma, Qiaoli, et al.
Publicado: (2018)

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
por: Zila, Nina, et al.
Publicado: (2018)

Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2021)

Addendum: Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2022)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)

Correction: Tusup et al. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA 2021, 7, 5
por: Tusup, Marina, et al.
Publicado: (2022)

Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages
por: Huber, Roman, et al.
Publicado: (2016)

Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2(S310F) mutated extramammary Paget’s disease
por: Nordmann, Thierry M., et al.
Publicado: (2019)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

Melanoma Immunotherapy: Next-Generation Biomarkers
por: Hogan, Sabrina A., et al.
Publicado: (2018)

Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice
por: Mangana, Joanna, et al.
Publicado: (2022)

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
por: Cheng, Phil F, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_00gch5r0u10j7dshkkeqn8pess